Estimating anti-amyloid therapy eligibility in Alzheimer's disease: A real-world retrospective study from an Italian memory clinic.
BackgroundAmyloid-targeting therapies (ATTs) such as donanemab may change the management of Alzheimer's disease (AD). However, ATTs require meticulous eligibility assessment to optimize the benefit-to-risk ratio.ObjectiveTo quantify the proportion of patients eligible for donanemab in a real-world Italian memory clinic...